Zydus Cadila receives final USFDA’s nod for Atenolol and Chlorthalidone Tablets

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Atenolol and Chlorthalidone Tablets USP (US RLD-Tenoretic), 50 mg/25 mg and 100 mg/25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. Atenolol belongs to a class of drugs known as beta blockers. Chlorthalidone is a ‘water pill’ (diuretic) and causes the body to get rid of extra salt and water. It also helps to relax the blood vessels so that blood can flow easily.

The group now has 253 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *